A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.
The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.
Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub. Brian Betts, MD, has joined Roswell Park as Vice Chair of Strategic Initiatives within the Transplant & Cellular Therapy Section, Department of Medicine; Kanwaldeep Mallhi, MD, was named Associate Professor of Oncology and Clinical Director of Pediatric Transplantation and Cellular Therapy in the Department of Pediatrics; and Shernan Holtan, MD, will join the Roswell Park faculty in February as Chief of Blood and Marrow Transplant in the Department of Medicine.
A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent years — a trend attributed to regular screening colonoscopies and lower smoking rates — the opposite is true for people born between 1981 and 1996, who have double the risk compared with people born in 1950. There’s an urgent need to identify more-effective therapies for those younger people: Approximately 58% of patients age 50 or under have advanced, distant disease at the time of diagnosis, and only 14% of that group will survive five years.
An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.
Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.
Evidence-based practice changes led by nurses from Roswell Park Comprehensive Cancer Center will be highlighted at the 48th annual Oncology Nursing Society (ONS) Congress April 26-30, 2023, in San Antonio, Texas.
Little is known about how radiation therapy to kill cancer cells affects immune cells and other components of patient tumors. But a study out of Roswell Park Comprehensive Cancer Center is shedding light on that process, providing information that could be key for planning treatment regimens that combine immunotherapy and radiation therapy. The authors outline their findings in a new study in the Journal for ImmunoTherapy of Cancer.
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
Research led by Roswell Park's Sarbajit Mukherjee, MD, MS, shows that a new chemotherapy combination — trifluridine/tipiracil (FTD/TPI) and oxaliplatin — is well tolerated and has activity among patients with esophageal cancer.
Results of an anonymous cancer patient and survivor survey conducted by a team from Roswell Park Comprehensive Cancer Center’s Center for Translational Research on Cannabis and Cancer (CTRCC) will be shared at the American Association for Cancer Research 2023 Annual Meeting in Orlando.
Based on a large retrospective study, Roswell Park Comprehensive Cancer Center experts that many patients with early-stage breast cancer with rare variant histology, or tumor anatomy, benefit from chemotherapy.
Vaping cannabidiol (CBD), a compound found in marijuana, leads to more severe lung damage than vaping nicotine, according to a study out of Roswell Park Comprehensive Cancer Center. Until now, research on the health effects of vaping, or using e-cigarettes, has focused almost exclusively on vaping nicotine as opposed to CBD. Previous research has documented the effects of smoking cannabis, but the effects of vaping cannabinoids such as CBD were not previously known.
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center. The study, “Association of neighborhood-level household income with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer,” appears today in JAMA Network Open.
Research at Roswell Park Comprehensive Cancer Center shows that putting a three-day limit on opioid prescriptions to treat surgical pain after hospital discharge reduces the number of patients who become chronic opioid users without compromising pain relief or recovery. It also reduces the amount of opioids circulating in the community — a grave concern, given that opioids are implicated in 130 overdose deaths in the U.S. every day.
A targeted therapy for children with high-risk Hodgkin lymphoma significantly reduced relapse rates, a large multicenter clinical trial conducted by the Children’s Oncology Group shows. The study results have been reported in the New England Journal of Medicine.
Roswell Park Comprehensive Cancer Center and Moffitt Cancer Center have partnered with more than 50 other cancer organizations to issue a call to action urging individuals, providers and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
T cells engineered to target the cell protein GPRC5D produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study in the New England Journal of Medicine.
The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).
New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.
A small molecule discovered and developed by a team of scientists led by Fengzhi Li, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, eliminates human pancreatic and colorectal tumor cells by binding to and degrading DDX5, a powerful cancer-causing protein.
Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.
Several nursing teams from Roswell Park Comprehensive Cancer Center were invited to share their research at the 47th Annual Congress of the Oncology Nursing Society (ONS), which is underway in Anaheim, California, and continues through May 1, 2022.